Viewing nowWidiang 25 mg Tablets (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Widus Pharmaceutical Co., Ltd.

MFDS item code 202102100 · Approved 2021.03.05 · Insurance code 660703920
Improvement of glycemic control in adults with type 2 diabetes
This medication is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It can also be administered as a monotherapy and, in some cases, is administered in combination with other diabetes medications such as metformin, pioglitazone, sulfonylureas, insulin, or the DPP-4 inhibitor linagliptin when existing diabetes medications are not effective. It is particularly suitable for patients who have difficulty controlling their blood sugar and requires careful management by a healthcare provider in patients with cardiovascular disease. This medication helps to improve effective blood sugar control and prevents diabetes-related complications, thereby enhancing the patient's health management.
The recommended dose of this drug is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this drug is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this drug is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 3. Adverse Reactions). This drug may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose on the same day. Special populations • Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Treatment with this drug should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this drug well but have a persistent eGFR < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This drug should be discontinued if the eGFR decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this drug in patients with end-stage renal disease (ESRD) or who are on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary for patients with mild or moderate hepatic impairment. Use of this drug is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this drug is not recommended in adults aged 85 years and older because clinical experience is limited (see Precautions, 4. General Precautions).
This medication should not be used by individuals allergic to the active ingredient or any of its components. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication should also not be used in patients with severely impaired kidney function, end-stage renal disease, or those undergoing dialysis. Patients with lactose intolerance or congenital lactose malabsorption should avoid this medication due to the lactose it contains. Patients with mildly impaired kidney function may need dose adjustment when taking this medication, and discontinuation is required if kidney function deteriorates further. Some heart failure patients have limited experience with this medication, so caution is needed, and it is not recommended for patients with severe heart failure. When this medication is used in conjunction with insulin or insulin secretagogues, the risk of hypoglycemia may increase; therefore, dosage adjustment may be necessary in such cases. During the course of treatment, patients should be vigilant for hypoglycemia symptoms, especially when combined with insulin or sulfonylureas, as hypoglycemia can occur. There is a possibility of urinary tract infections or genital infections, so if any infection symptoms appear, immediate consultation with a healthcare provider is advised. Increased urination may occur, which can cause discomfort. Hypotension or dehydration may result from fluid volume loss, so caution is particularly advised for elderly patients or those with low blood pressure. Rarely, severe metabolic abnormalities such as ketoacidosis can occur; patients should seek immediate medical attention if symptoms such as nausea, vomiting, abdominal pain, or shortness of breath occur. This medication is not recommended for use during pregnancy, and it should be discontinued if pregnancy is confirmed. Breastfeeding women should stop nursing while taking this medication, as it may affect the nursing infant. Children under 18 years old should not use this medication as its safety and efficacy have not been established. No specific toxicity has been reported in case of overdose, although appropriate treatment may be required depending on clinical condition. This medication should be kept out of the reach of children and should not be transferred to another container. Caution is required when driving or operating machinery due to the risk of hypoglycemia. Serious side effects such as limb amputation have been reported rarely, so diabetic patients should pay attention to foot care. Rare infectious diseases such as perineal necrotizing fasciitis may occur, so if there is pain or abnormal sensations in that area, immediate medical consultation is required. This medication may interact with other drugs, so patients should inform their doctor or pharmacist about any medications they are taking.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and moisture. The safe storage temperature is between 1 and 30 degrees Celsius at room temperature. Proper storage will maintain the medication's efficacy and prevent deterioration.
Light yellow, oval, film-coated tablet with a biconvex shape
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
Widus Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.